<DOC>
	<DOCNO>NCT00911183</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cyclophosphamide , vincristine sulfate , prednisone , liposome-encapsulated doxorubicin citrate , work different way stop growth cancer cell , either kill cell stop dividing . It yet know whether rituximab combination chemotherapy effective give together without liposome-encapsulated doxorubicin citrate treat old patient diffuse large B-cell non-Hodgkin lymphoma . PURPOSE : This randomized phase II trial study side effect give rituximab together cyclophosphamide , vincristine sulfate , prednisone without liposome-encapsulated doxorubicin citrate see well work treat old patient stage II , stage III , stage IV diffuse large B-cell non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Rituximab , Cyclophosphamide , Vincristine Sulfate , Prednisone With Without Liposome-Encapsulated Doxorubicin Citrate Treating Older Patients With Stage II , Stage III , Stage IV Diffuse Large B-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess therapeutic efficacy rituximab , cyclophosphamide , vincristine sulfate , prednisone v without liposome-encapsulated doxorubicin citrate , term complete remission rate 6 month , vulnerable frail elderly patient stage II , III , IV diffuse large B-cell non-Hodgkin lymphoma . - To assess safety regimen patient . Secondary - To evaluate progression-free survival , event-free survival , overall survival rate 6 24 month patient treat regimen . - To evaluate overall response rate 6 24 month patient treat regimen . - To evaluate duration complete remission patient treat regimen . - To evaluate acute side effect ( accord International CTC scale ) regimens patient . - To evaluate geriatric condition quality life patient treat regimen . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I ( R-COP regimen ) : Patients receive rituximab IV , cyclophosphamide IV , vincristine sulfate IV day 1 . Patients also receive oral prednisone day 1-5 filgrastim subcutaneously ( SC ) day 8-14 pegfilgrastim SC day 2 . Treatment repeat every 21 day least 3 course . - Arm II ( R-COPY regimen ) : Patients receive rituximab , cyclophosphamide , vincristine sulfate , prednisone , filgrastim pegfilgrastim arm I . Patients also receive liposome-encapsulated doxorubicin citrate IV day 1 . Treatment repeat every 21 day least 3 course . After 3 course R-COP R-COPY , patient undergo evaluation . Patients disease progression response &lt; 25 % remove study . Patients response ≥ 25 % receive 3 course R-COP R-COPY , follow rituximab IV alone day 1 course 7 8 absence disease progression unacceptable toxicity . After completion chemotherapy , patient may undergo radiotherapy . Patients complete quality life geriatric assessment questionnaire baseline periodically study treatment . After completion study treatment , patient follow every 3 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis diffuse large Bcell nonHodgkin lymphoma Stage II , III , IV disease ( accord WHO classification ) , include morphological clinical variant No Burkittlike lymphoma ( presence small cell bone marrow biopsy allow ) CD20+ disease Has ≥ 1 measurable target lesion ≥ 1.1 cm ( accord International Workshop Criteria ) Poor physiological status , define ≥ 1 follow criterion : WHO performance status 3 Clinical evaluation measurement LVEF would preclude doxorubicin administration ( i.e. , LVEF &lt; 50 % ) Creatinine clearance &lt; 50 mL/min Serum bilirubin &gt; 30 μmol/L Severe comorbidity would preclude use CHOP chemotherapy Ineligible standard RCHOP therapy No cerebral meningeal involvement PATIENT CHARACTERISTICS : WHO performance status 03 ANC &gt; 750/mm^3 Platelet count &gt; 50,000/mm^3 LVEF &gt; 35 % Able receive either RCOP RCOPY therapy No congestive heart failure , serious arrhythmia , myocardial infarction within past 6 month No malignancy within past 5 year except adequately treat basal cell carcinoma skin curatively treat carcinoma situ cervix No active infection No active viral hepatitis B C serology No known HIV positivity No hypersensitivity rituximab , excipients , murine proteins No documented history allergy egg egg product No psychological , familial , sociological , geographical condition would preclude compliance study treatment followup schedule PRIOR CONCURRENT THERAPY : No prior therapy cancer No prior anthracycline administration cumulative dose &gt; 240 mg/m² doxorubicin hydrochloride &gt; 400 mg/m² epirubicin hydrochloride More 30 day since prior participation another clinical trial involve investigational drug No concurrent antineoplastic agent</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>